Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Tomomi Kuramoto is active.

Publication


Featured researches published by Tomomi Kuramoto.


BJUI | 2010

Insulin resistance increases the risk of urinary stone formation in a rat model of metabolic syndrome

Akinori Iba; Yasuo Kohjimoto; Takashi Mori; Tomomi Kuramoto; Satoshi Nishizawa; Reona Fujii; Yoshihito Nanpo; Nagahide Matsumura; Yasuyo Shintani; Takeshi Inagaki; Isao Hara

To investigate the association between metabolic syndrome and urinary stone disease, and whether insulin resistance associated with adiposity affects the risk of urinary stone formation, using a rat model of metabolic syndrome.


Urology | 2009

Squamous Cell Carcinoma of the Urachus Producing Granulocyte Colony-Stimulating Factor

Tomomi Kuramoto; Kazuro Kikkawa; Masaya Nishihata; Nagahide Matsumura; Yasuo Kohjimoto; Takeshi Inagaki; Yasunari Uekado; Isao Hara

Urachal carcinoma is a rare cancer. This is the first report of a case of squamous cell carcinoma of the urachus producing granulocyte colony-stimulating factor. The patient underwent partial cystectomy with urachal remnant resection and pelvic lymphadenectomy. No evidence of tumor recurrence or metastasis was found at 17 months after surgery.


Urology | 2009

Dendritic cells with transduced survivin gene induce specific cytotoxic T lymphocytes in human urologic cancer cell lines.

Kazuro Kikkawa; Reona Fujii; Tomomi Kuramoto; Takashi Mori; Takeshi Inagaki; Yasuo Kohjimoto; Makoto Iwahashi; Hiroki Yamaue; Isao Hara

OBJECTIVES To investigate whether survivin-specific cytotoxic T lymphocytes (CTLs) could be induced by dendritic cells (DCs) transduced with survivin gene by adenoviral vector, and whether these CTLs would display cytotoxic activities against human urologic cancer cell lines. Survivin, a member of the inhibitor of apoptosis protein family, is expressed in most malignancies, but not in normal tissue. METHODS Adenoviral vector encoding the human survivin gene was generated. Human DCs from healthy donors were transduced with human survivin gene by infection with adenoviral vector encoding the human survivin gene using the centrifugal method. Survivin-specific CTLs were induced from autologous peripheral blood mononuclear cells by DCs transduced with the survivin gene. The ability of CTLs to lyse cancer cell lines was assessed using the (51)Cr-release assay. RESULTS DCs transduced with survivin gene could induce survivin-specific CTLs against various urologic malignancies such as bladder, kidney, and prostate cancer cells. This cytotoxic activity could be blocked by anti-CD8 and anti-major histocompatibility complex class I antibodies. We also found that this cytotoxic activity was specific for the survivin protein and human leukocyte antigen haplotype. CONCLUSIONS DCs transduced with the survivin gene induced potent survivin-specific CTL responses in vitro. This suggests that cancer immunotherapy targets for survivin might offer a novel approach to treating various urologic cancers.


Case reports in urology | 2013

Cholestatic Jaundice as a Paraneoplastic Manifestation of Prostate Cancer

Tomomi Kuramoto; Hiroya Senzaki; Hiroyuki Koike; Kenji Yamagiwa; Shinobu Tamura; Tokuzou Fujimoto; Takeshi Inagaki

Paraneoplastic syndrome associated with prostate cancer is extremely rare. We report a patient who presented with cholestatic jaundice without biliary duct obstruction, hepatic involvement, or infection. After a few detailed examinations, prostate cancer was diagnosed. After treatment with bicalutamide and leuprolide, the patients symptoms and laboratory abnormalities were reversed. Cholestatic jaundice was regarded as a paraneoplastic manifestation in this patient. The patient remains symptom-free after 14-month followup. Paraneoplastic syndrome should be considered in case of cholestatic jaundice without biliary duct obstruction, hepatic involvement, or infection.


International Journal of Urology | 2009

PSA at postoperative three months can predict biochemical recurrence in patients with pathological T3 prostate cancer following radical prostatectomy

Takeshi Inagaki; Yasuo Kohjimoto; Satoshi Nishizawa; Tomomi Kuramoto; Yoshihito Nanpo; Reona Fujii; Nagahide Matsumura; Yasuyo Shintani; Yasunari Uekado; Isao Hara

Objectives:  To identify the prognostic factors and determine which pT3 prostate cancer patients can be safely followed up after surgery without any adjuvant treatment.


BJUI | 2009

Bacillus Calmette‐Guérin cell‐wall skeleton enhances the killing activity of cytotoxic lymphocyte‐activated human dendritic cells transduced with the prostate‐specific antigen gene

Reona Fujii; Makoto Iwahashi; Kazuro Kikkawa; Takeshi Inagaki; Yasuo Kohjimoto; Toshiyasu Ojima; Takashi Mori; Tomomi Kuramoto; Satoshi Nishizawa; Ichiro Azuma; Hiroki Yamaue; Toshiaki Shinka; Isao Hara

To determine whether dendritic cells (DC) transduced with the prostate‐specific antigen (PSA) gene can induce PSA‐specific cytotoxic lymphocytes (CTL) against prostate cancer cells, and whether bacillus Calmette‐Guérin (BCG) cell‐wall skeleton (CWS) can enhance the maturation of DC‐PSA and the killing activity of subsequently induced PSA‐specific CTL.


BJUI | 2011

IL‐23 gene therapy for mouse bladder tumour cell lines

Tomomi Kuramoto; Reona Fujii; Hiroshi Nagai; Maria Laura Belladonna; Takayuki Yoshimoto; Yasuo Kohjimoto; Takeshi Inagaki; Isao Hara

•  To evaluate the antitumour effects of IL‐23 gene transfer into mouse bladder carcinoma (MBT2) cells. •  To investigate the mechanisms underlying the subsequent constitutive secrection of IL‐23 by the MBT2 cells


The Journal of Urology | 2008

THE FEASIBILITY AND USEFULNESS OF JAPAN ASSOCIATION FOR THE SURGERY OF TRAUMA (JAST) CLASSIFICATION FOR BLUNT RENAL TRAUMA

Satoshi Nishizawa; Takashi Mori; Tomomi Kuramoto; Akinori Iba; Yoshihito Nanpo; Reona Fujii; Nagahide Matsumura; Yasuyo Shintani; Takeshi Inagaki; Yasuo Kojimoto; Isao Hara

RESULTS: The average follow-up was 50 months (range 12 to 132 months). The stricture etiology was catheter in 20 (32.3%) cases, unknown in 19 (32.3%), instrumentation in 17 (27.4%), trauma in 4 (6.5%), radiotherapy in 1 (1.6%) and infection in 1 (1.6%). Stricture length was: 4- 6 cm in 13 (21%), 3-<4 cm in 10 (16.1%), 2-<3 cm in 8 (12.9%), 1<2cm in 2 (3.2%). Fifty-one patients (82.2%) underwent dilation (12.9%), internal urethrotomy (17.7%), urethroplasty (4.8%) or multiple treatments (46.9%) before referral to our center. Out of 62 cases, 47 (75.8%) were successful and 15 (24.2%) failures. Out of 18 cases that underwent one-stage dartos


The Journal of Urology | 2009

QUALITY OF LIFE ANALYSIS OF PATIENTS WHO UNDERWENT HIGH DOSE RATE BRACHYTHERAPY WITH EXTERNAL BEAM RADIOTHERAPY (HDR+EBRT) COMPARING WITH THOSE WHO HAD RETROPUBIC RADICAL PROSTATECTOMY (RRP)

Takeshi Inagaki; Yasuo Kohjimoto; Takashi Mori; Tomomi Kuramoto; Satoshi Nishizawa; Reona Fujii; Yoshihito Nampo; Nagahide Matsumura; Yasuyo Shintani; Shintaro Shirai; Morio Sato; Isao Hara

The mean age of BT and RP treated patients was 68 and 64 years. 71,7% (n=620) of RP treated patients had non-nerve-sparing surgery. 89,3% (n=303) and 90,6% (n=770) of the BT and RP treated patients had clinical tumor stage of cT1a-2b. Significant better results in concern of increased voiding frequency (BT 67,8% vs. RP 60,4%), nocturia (BT 43,7% vs. RP 28,9%) and urge symptoms (BT 47,4% vs. RP 36,4%) were recognized at the RP treated group. Significant better results in term of incontinence was achieved in the BT group (BT 11,6% vs. RP 15,6%), but interestingly the group with nerve sparing RP showed almost similar results to BT (BT 11,6% and nerve-sparing RP 11,2%). Absence of erections was reported by 43% of the BT, 85% of RP without nerve sparing, 45% of RP with unilateral nerve sparing and 38% of the RP with bilateral nerve sparing. CONCLUSIONS: In regards to functional outcome BT causes significant higher rates of irritative voiding symptoms. However continence and Preservation of erectile function seems superior in BT compared to RP patients without nerve sparing. Nevertheless differences became minor or insignificant in RP with bilateral nerve sparing.


International Journal of Clinical Oncology | 2013

Docetaxel in combination with estramustine and prednisolone for castration-resistant prostate cancer

Tomomi Kuramoto; Takeshi Inagaki; Reona Fujii; Yumiko Sasaki; Satoshi Nishizawa; Yoshihito Nanpo; Nagahide Matusmura; Yasuo Kohjimoto; Isao Hara

Collaboration


Dive into the Tomomi Kuramoto's collaboration.

Top Co-Authors

Avatar

Yasuo Kohjimoto

Wakayama Medical University

View shared research outputs
Top Co-Authors

Avatar

Isao Hara

Wakayama Medical University

View shared research outputs
Top Co-Authors

Avatar

Reona Fujii

Wakayama Medical University

View shared research outputs
Top Co-Authors

Avatar

Takashi Mori

Wakayama Medical University

View shared research outputs
Top Co-Authors

Avatar

Takeshi Inagaki

Wakayama Medical University

View shared research outputs
Top Co-Authors

Avatar

Satoshi Nishizawa

Wakayama Medical University

View shared research outputs
Top Co-Authors

Avatar

Nagahide Matsumura

Wakayama Medical University

View shared research outputs
Top Co-Authors

Avatar

Yasuyo Shintani

Wakayama Medical University

View shared research outputs
Top Co-Authors

Avatar

Takeshi Inagaki

Wakayama Medical University

View shared research outputs
Top Co-Authors

Avatar

Akinori Iba

Wakayama Medical University

View shared research outputs
Researchain Logo
Decentralizing Knowledge